[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Randomized Clinical Trial Evaluating Differences in Postoperative Symptoms With 6Fr Percuflex Ureteral Stents Versus 6Fr Tria Ureteral Stents Versus 4.8Fr Percuflex Ureteral Stents Versus 4.8Fr Tria Ureteral Stents After Laser Lithotripsy of Renal and Ureteral Stones


Description

This is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents, and 4.8Fr Tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of upper tract urinary stones. 272 participants will be enrolled and will be on study for up to approximately 10 weeks.The investigators will compare Ureteral Stent Symptom Questionnaire (USSQ) scores with each ureteral stent. Laser lithotripsy is a surgical procedure performed during stone surgeries. The Percuflex ureteral stent and Tria ureteral stent are FDA approved and clinically used in the United States. A total of 3 clinic visits (i.e., pre-operative visit, the stent removal 1-2 weeks after surgery, and one post-operative visit 3-6 weeks after surgery) in addition to the surgery will be needed for this study. The patient's demographic information and medical background

Trial Eligibility

Inclusion Criteria: * Patients with renal or ureteral urinary stones who require endoscopic treatment and stent placement in the outpatient operating room. Exclusion Criteria: * Pregnant patients * Patients with transplant kidneys * Patients with irreversible coagulopathy * Patients with known ureteral stricture disease * Non-English speaking, vulnerable patients such as lacking of decision-making capability, prisoner, adult unable to consent, will not be enrolled. * Patients with planned staged procedures. * Patients who have stent placed before surgery.

Study Info

Organization

University of Wisconsin, Madison


Primary Outcome

Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms


Outcome Timeframe at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)

NCTID NCT06083051

Phases NA

Primary Purpose TREATMENT

Start Date 2024-03-21

Completion Date 2025-07

Enrollment Target 272

Interventions

DEVICE 6Fr Percuflex ureteral stents

DEVICE 6Fr Tria ureteral stents

DEVICE 4.8Fr Tria ureteral stents

DEVICE 4.8Fr Percuflex ureteral stents

Locations Recruiting

University of Wisconsin School of Medicine and Public Health

United States, Wisconsin, Madison


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Hairy Cell Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.